WO2011070253A8 - Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents

Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDF

Info

Publication number
WO2011070253A8
WO2011070253A8 PCT/FR2010/000823 FR2010000823W WO2011070253A8 WO 2011070253 A8 WO2011070253 A8 WO 2011070253A8 FR 2010000823 W FR2010000823 W FR 2010000823W WO 2011070253 A8 WO2011070253 A8 WO 2011070253A8
Authority
WO
WIPO (PCT)
Prior art keywords
same
azabicyclo
hex
derivatives
pharmaceutical compositions
Prior art date
Application number
PCT/FR2010/000823
Other languages
English (en)
Other versions
WO2011070253A1 (fr
Inventor
Patrick Casara
Anne-Marie Chollet
Alain Dhainaut
Jean-Michel Henlin
Pierre Lestage
Fany Panayi
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42711699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011070253(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN2010800559947A priority Critical patent/CN102652127A/zh
Priority to IN4966DEN2012 priority patent/IN2012DN04966A/en
Priority to MX2012006578A priority patent/MX2012006578A/es
Priority to AU2010329762A priority patent/AU2010329762B2/en
Priority to MA34932A priority patent/MA33882B1/fr
Priority to EP10799080A priority patent/EP2509947A1/fr
Priority to JP2012542591A priority patent/JP2013513589A/ja
Priority to AP2012006352A priority patent/AP2012006352A0/xx
Priority to US13/514,796 priority patent/US20120283245A1/en
Priority to EA201200849A priority patent/EA201200849A1/ru
Priority to BR112012013666A priority patent/BR112012013666A2/pt
Priority to SG2012038931A priority patent/SG181082A1/en
Priority to UAA201208178A priority patent/UA102950C2/ru
Priority to CA2782469A priority patent/CA2782469C/fr
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of WO2011070253A1 publication Critical patent/WO2011070253A1/fr
Priority to TNP2012000267A priority patent/TN2012000267A1/fr
Priority to ZA2012/03943A priority patent/ZA201203943B/en
Publication of WO2011070253A8 publication Critical patent/WO2011070253A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composés de formule (I) : dans laquelle : ALK représente une chaîne alkylène, W représente un groupement de formule (II) ou de formule (III) où R et R' sont tels que définis dans la description. Médicament.
PCT/FR2010/000823 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent WO2011070253A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IN4966DEN2012 IN2012DN04966A (fr) 2009-12-09 2010-12-08
EA201200849A EA201200849A1 (ru) 2009-12-09 2010-12-08 Новые азабицикло[3.1.0]гекс-2-ильные соединения, способ их получения и фармацевтические композиции, содержащие их
US13/514,796 US20120283245A1 (en) 2009-12-09 2010-12-08 Azabicyclo[3.1.0]hex-2-yl compounds, a process for their preparation and pharmaceutical compositions containing them
AU2010329762A AU2010329762B2 (en) 2009-12-09 2010-12-08 Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
MA34932A MA33882B1 (fr) 2009-12-09 2010-12-08 Nouveaux derives azabicyclo [3.1.0]hex-2-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP10799080A EP2509947A1 (fr) 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0]hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2012542591A JP2013513589A (ja) 2009-12-09 2010-12-08 アザビシクロ［３．１．０］ヘキサ−２−イル誘導体、その調製方法、及びそれを含有する医薬組成物
AP2012006352A AP2012006352A0 (en) 2009-12-09 2010-12-08 AzabicycloÄ3.1.0Ühex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same.
MX2012006578A MX2012006578A (es) 2009-12-09 2010-12-08 Derivados de azabiciclo[3.1.0]hex-2-ilo, metodo para prepararlos, y composiciones farmaceuticas que los contienen.
CN2010800559947A CN102652127A (zh) 2009-12-09 2010-12-08 氮杂双环[3.1.0]己-2-基衍生物、制备方法和包含它们的药物组合物
SG2012038931A SG181082A1 (en) 2009-12-09 2010-12-08 Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same
BR112012013666A BR112012013666A2 (pt) 2009-12-09 2010-12-08 compostos de azabiciclo[3.1.0]hex-2-ila, processo para sua preparação e composições farmacêuticas que os contêm
UAA201208178A UA102950C2 (ru) 2009-12-09 2010-12-08 Азабицикло[3.1.0]гекс-2-иловые соединения, способ их получения и фармацевтическая композиция, которая их содержит
CA2782469A CA2782469C (fr) 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TNP2012000267A TN2012000267A1 (fr) 2009-12-09 2012-05-28 Nouveaux derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ZA2012/03943A ZA201203943B (en) 2009-12-09 2012-05-30 New azabicyclo[3.1.0]hex-2-yl compounds,a process for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR09.05953 2009-12-09
FR0905953A FR2953521B1 (fr) 2009-12-09 2009-12-09 Nouveaux derives azabicyclo[3.1.0]hex-2-yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
WO2011070253A1 WO2011070253A1 (fr) 2011-06-16
WO2011070253A8 true WO2011070253A8 (fr) 2012-08-02

Family

ID=42711699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/000823 WO2011070253A1 (fr) 2009-12-09 2010-12-08 Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Country Status (31)

Country Link
US (1) US20120283245A1 (fr)
EP (1) EP2509947A1 (fr)
JP (1) JP2013513589A (fr)
KR (1) KR20120102763A (fr)
CN (1) CN102652127A (fr)
AP (1) AP2012006352A0 (fr)
AR (1) AR079265A1 (fr)
AU (1) AU2010329762B2 (fr)
BR (1) BR112012013666A2 (fr)
CA (1) CA2782469C (fr)
CL (1) CL2012001479A1 (fr)
CO (1) CO6541535A2 (fr)
CR (1) CR20120286A (fr)
CU (1) CU20120091A7 (fr)
EA (1) EA201200849A1 (fr)
EC (1) ECSP12011950A (fr)
FR (1) FR2953521B1 (fr)
GE (1) GEP20156227B (fr)
IN (1) IN2012DN04966A (fr)
MA (1) MA33882B1 (fr)
MX (1) MX2012006578A (fr)
NI (1) NI201200099A (fr)
PE (1) PE20121475A1 (fr)
SA (1) SA110320011B1 (fr)
SG (1) SG181082A1 (fr)
TN (1) TN2012000267A1 (fr)
TW (1) TW201200499A (fr)
UA (1) UA102950C2 (fr)
UY (1) UY33072A (fr)
WO (1) WO2011070253A1 (fr)
ZA (1) ZA201203943B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015032966A1 (fr) * 2013-09-09 2015-03-12 Sanofi Antagoniste des récepteurs h3 combiné à un inhibiteur de la cholinestérase et utilisé dans le cadre du traitement de la maladie d'alzheimer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
DE602006014022D1 (de) * 2005-11-30 2010-06-10 Hoffmann La Roche 5-substituierte indol-2-carbonsäureamidderivate

Also Published As

Publication number Publication date
CN102652127A (zh) 2012-08-29
WO2011070253A1 (fr) 2011-06-16
SA110320011B1 (ar) 2013-10-01
FR2953521B1 (fr) 2011-11-18
EP2509947A1 (fr) 2012-10-17
BR112012013666A2 (pt) 2016-04-19
CO6541535A2 (es) 2012-10-16
CA2782469A1 (fr) 2011-06-16
JP2013513589A (ja) 2013-04-22
ZA201203943B (en) 2013-08-28
ECSP12011950A (es) 2012-07-31
UY33072A (es) 2011-05-31
CU20120091A7 (es) 2012-07-31
UA102950C2 (ru) 2013-08-27
MX2012006578A (es) 2012-06-25
US20120283245A1 (en) 2012-11-08
AU2010329762A1 (en) 2012-06-21
NI201200099A (es) 2012-11-09
EA201200849A1 (ru) 2013-01-30
IN2012DN04966A (fr) 2015-09-25
CR20120286A (es) 2012-08-20
GEP20156227B (en) 2015-01-26
TW201200499A (en) 2012-01-01
PE20121475A1 (es) 2012-10-20
SG181082A1 (en) 2012-07-30
TN2012000267A1 (fr) 2013-12-12
KR20120102763A (ko) 2012-09-18
AR079265A1 (es) 2012-01-04
MA33882B1 (fr) 2013-01-02
FR2953521A1 (fr) 2011-06-10
CL2012001479A1 (es) 2013-02-08
AP2012006352A0 (en) 2012-08-31
CA2782469C (fr) 2014-04-08
AU2010329762B2 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
TW200732323A (en) Organic compounds
NZ593951A (en) Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2008003766A3 (fr) Nouveaux composés
MX2012008260A (es) Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
MX2011012122A (es) Derivados de tiofeno.
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MY150497A (en) New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
WO2008006795A3 (fr) Composés d'indole
WO2009105969A8 (fr) Analogues d'épothilone, leurs compositions pharmaceutiques, leur utilisation et leurs préparations
WO2007130821A3 (fr) Modulateurs des récepteurs de mglur5 ii
WO2012051407A3 (fr) Contenants moléculaires ainsi que leurs méthodes de fabrication et d'utilisation
WO2010049449A3 (fr) Nouveaux sels de sunitinib
IN2012DN01292A (fr)
WO2007095021A3 (fr) Nouveaux composés
WO2011047055A3 (fr) Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
WO2009021943A3 (fr) Nouveau procédé de préparation
WO2011070253A8 (fr) Derives azabicyclo [3.1.0] hex- 2 -yl, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2008062167A3 (fr) Dérivés de mélatonine utilisés comme antioxydants
WO2009152474A3 (fr) Procédé de préparation de dérivés de (3s)-3-amino-n-cyclopropyl-2-hydroxyalcanamide
WO2009030725A3 (fr) Azaindoles inhibiteurs d'adénylate cyclase soluble

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080055994.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10799080

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010799080

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 000722-2012

Country of ref document: PE

Ref document number: 12012501053

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: CR2012-000286

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2782469

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010329762

Country of ref document: AU

Ref document number: 220072

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2012001479

Country of ref document: CL

Ref document number: 4966/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012542591

Country of ref document: JP

Ref document number: MX/A/2012/006578

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010329762

Country of ref document: AU

Date of ref document: 20101208

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12774

Country of ref document: GE

Ref document number: A201208178

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201200849

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20127017843

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13514796

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012013666

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012013666

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120606